(Q48897517)

16 February 2018

title

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial (English)

1 reference

16 February 2018

main subject

phase III clinical trial

0 references

0 references

1 reference

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

8

1 reference

16 February 2018

Jeffrey L. Cummings

1

object named as

Jeffrey Cummings

1 reference

16 February 2018

Stuart Isaacson

2

1 reference

16 February 2018

Roger Mills

3

1 reference

16 February 2018

Hilde Williams

4

1 reference

16 February 2018

Kathy Chi-Burris

5

1 reference

16 February 2018

Anne Corbett

6

1 reference

16 February 2018

Rohit Dhall

7

1 reference

16 February 2018

language of work or name

English

0 references

publication date

1 November 2013

1 reference

16 February 2018

published in

The Lancet

1 reference

16 February 2018

volume

383

1 reference

16 February 2018

issue

9916

1 reference

16 February 2018

page(s)

533-540

1 reference

16 February 2018

Psychiatric syndromes in Parkinson's disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Quetiapine for agitation or psychosis in patients with dementia and parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Serotonin 2A receptors and visual hallucinations in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Human genetic variations in the 5HT2A receptor: a single nucleotide polymorphism identified with altered response to clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Assessment of sleep and sleepiness in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Determining the minimum clinically important differences for outcomes in the DOMINO trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962106-6

7 January 2021

10.1016/S0140-6736(13)62106-6

Identifiers

DOI

1 reference

16 February 2018

1 reference

16 February 2018